CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
CERo Therapeutics (Nasdaq: CERO) has secured a Series D financing agreement for up to $8 million through a convertible preferred stock transaction. The financing includes an initial $5 million investment at first closing, with potential additional funding of up to $3 million in subsequent closings at investors' discretion.
The company plans to utilize the proceeds to leverage its recent FDA IND allowances in liquid and solid tumors, complete site activation at MD Anderson Cancer Center (MDACC), and accelerate additional site activations. The funding will also help address Nasdaq shareholders equity requirements and extend operational runway.
CERo Therapeutics (Nasdaq: CERO) ha ottenuto un accordo di finanziamento di Serie D fino a 8 milioni di dollari tramite una transazione di azioni privilegiate convertibili. Il finanziamento prevede un investimento iniziale di 5 milioni di dollari al primo closing, con un possibile finanziamento aggiuntivo fino a 3 milioni di dollari in chiusure successive a discrezione degli investitori.
L'azienda intende utilizzare i fondi per sfruttare le recenti autorizzazioni FDA IND nei tumori liquidi e solidi, completare l'attivazione del sito presso il MD Anderson Cancer Center (MDACC) e accelerare ulteriori attivazioni di siti. Il finanziamento servirà anche a soddisfare i requisiti patrimoniali degli azionisti Nasdaq e a prolungare la durata operativa.
CERo Therapeutics (Nasdaq: CERO) ha asegurado un acuerdo de financiamiento de Serie D por hasta 8 millones de dólares mediante una transacción de acciones preferentes convertibles. El financiamiento incluye una inversión inicial de 5 millones de dólares en el primer cierre, con un posible financiamiento adicional de hasta 3 millones de dólares en cierres posteriores a discreción de los inversionistas.
La compañía planea utilizar los fondos para aprovechar sus recientes aprobaciones FDA IND en tumores líquidos y sólidos, completar la activación del sitio en el MD Anderson Cancer Center (MDACC) y acelerar la activación de sitios adicionales. La financiación también ayudará a cumplir con los requisitos de patrimonio de los accionistas de Nasdaq y a extender el tiempo operativo.
CERo Therapeutics (나스닥: CERO)는 전환 우선주 거래를 통해 최대 800만 달러 규모의 시리즈 D 자금 조달 계약을 체결했습니다. 이번 자금 조달에는 첫 클로징 시 500만 달러의 초기 투자와 투자자 재량에 따른 이후 클로징에서 최대 300만 달러의 추가 자금이 포함됩니다.
회사는 이번 자금을 최근 FDA IND 승인받은 액체 및 고형 종양 분야에 활용하고, MD 앤더슨 암 센터(MDACC)에서 사이트 활성화를 완료하며 추가 사이트 활성화를 가속화할 계획입니다. 또한 이번 자금은 나스닥 주주 지분 요건을 충족하고 운영 자금을 연장하는 데에도 사용됩니다.
CERo Therapeutics (Nasdaq : CERO) a conclu un accord de financement de série D pouvant atteindre 8 millions de dollars via une transaction d’actions privilégiées convertibles. Le financement comprend un investissement initial de 5 millions de dollars lors de la première clôture, avec un financement supplémentaire potentiel pouvant atteindre 3 millions de dollars lors de clôtures ultérieures à la discrétion des investisseurs.
L’entreprise prévoit d’utiliser les fonds pour tirer parti de ses récentes autorisations FDA IND dans les tumeurs liquides et solides, finaliser l’activation du site au MD Anderson Cancer Center (MDACC) et accélérer l’activation de sites supplémentaires. Ce financement contribuera également à répondre aux exigences de capitaux propres des actionnaires Nasdaq et à prolonger la durée opérationnelle.
CERo Therapeutics (Nasdaq: CERO) hat eine Series-D-Finanzierungsvereinbarung über bis zu 8 Millionen US-Dollar durch eine Transaktion mit wandelbaren Vorzugsaktien gesichert. Die Finanzierung umfasst eine anfängliche Investition von 5 Millionen US-Dollar beim ersten Closing, mit der Möglichkeit zusätzlicher Mittel von bis zu 3 Millionen US-Dollar bei nachfolgenden Closings nach Ermessen der Investoren.
Das Unternehmen plant, die Mittel zu nutzen, um die kürzlich erhaltenen FDA IND-Zulassungen bei flüssigen und soliden Tumoren zu nutzen, die Standortaktivierung am MD Anderson Cancer Center (MDACC) abzuschließen und weitere Standortaktivierungen zu beschleunigen. Die Finanzierung wird auch dazu beitragen, die Eigenkapitalanforderungen der Nasdaq-Aktionäre zu erfüllen und die operative Laufzeit zu verlängern.
- Secured up to $8M in Series D financing
- Received FDA IND allowances for both liquid and solid tumors
- Imminent first patient dosing at MD Anderson Cancer Center
- Funding helps address Nasdaq compliance issues
- Potential shareholder dilution through convertible preferred stock issuance
- Full financing dependent on investor discretion for remaining $3M
- Current Nasdaq deficiencies in Shareholders Equity
Insights
CERo secures critical $8M financing to advance clinical trials following FDA approvals while addressing Nasdaq compliance issues.
CERo Therapeutics has secured up to
The timing aligns strategically with two recent FDA IND allowances for the company's therapies in both liquid and solid tumors. Management has explicitly indicated the proceeds will serve three critical purposes: 1) capitalize on FDA approvals by completing site activation at MD Anderson Cancer Center, 2) activate additional clinical sites, and 3) address Nasdaq deficiencies related to Shareholders' Equity requirements.
The reference to addressing Nasdaq compliance issues indicates the company has been facing potential delisting concerns, which this financing aims to resolve. The funding structure—with only
For a clinical-stage biotech transitioning from preclinical to human studies, securing capital during challenging market conditions demonstrates management's ability to support critical value-creating clinical milestones. The CEO's reference to "imminent dosing" of their first AML patient signals that clinical progression is at a pivotal juncture, with this financing enabling the company to maintain operational momentum.
Strategic financing enables CERo to advance novel T cell immunotherapies into clinical testing following FDA approvals for dual cancer indications.
CERo Therapeutics has secured crucial financing to advance its innovative engineered T cell therapeutics platform employing phagocytic mechanisms. The company has recently achieved significant regulatory milestones with FDA IND allowances for both liquid and solid tumor applications, indicating regulatory validation of their preclinical package and clinical protocols.
The financing comes at a critical inflection point as the company prepares for "imminent dosing" of its first AML (acute myeloid leukemia) patient at MD Anderson Cancer Center, a top-tier cancer research institution. Site activation at prestigious clinical centers represents a significant operational hurdle for emerging biotechs and requires substantial resources to complete.
CERo's technology platform appears to be differentiated by incorporating phagocytic mechanisms into engineered T cell therapeutics, potentially offering advantages over current approaches. The dual IND allowances for both liquid and solid tumors suggest platform versatility across different cancer types, which increases the technology's potential value proposition.
The funding enables CERo to transition from a preclinical-stage company to a clinical-stage organization—a critical value-creating milestone in biotech development. This progression to clinical testing will generate human safety and efficacy data that will be essential for validating their technological approach and determining the clinical potential of their therapeutic candidates.
SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.
The gross proceeds to CERo from the offering are expected to be up to
“On the heels of our recent announcements anticipating the imminent dosing of our first AML patient at MD Anderson Cancer Center and the IND allowance in solid tumors, we are gratified by the support we have received from investors and look forward to continued execution and progress,” said Chris Ehrlich, Chief Executive Officer.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo and the implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
What is the total value of CERo Therapeutics' Series D financing round?
How will CERo (CERO) use the Series D financing proceeds?
What recent regulatory approvals has CERo Therapeutics received?
Which medical center is CERo partnering with for clinical trials?
